U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827989) titled 'Study of the Impact of Phosphate Supplementation on FGF23 Concentrations in Patients With Hypophosphatemia' on Sept. 11.
Brief Summary: Fibroblast growth factor 23 (FGF23) is the principal hormone regulating serum phosphate homeostasis. Secreted by osteocytes, it promotes renal phosphate excretion and suppresses the synthesis of 1,25-dihydroxyvitamin D. Measurement of FGF23 has become a key tool in the evaluation of hypophosphatemia, allowing distinction between FGF23-dependent forms (such as X-linked hypophosphatemic rickets, tumor-induced osteomalacia, and intravenous iron-induced hypophosphatemia) and FGF23-independent forms (in...